Navigation Links
Hard To Treat Diseases (HTDS) Closes Acquisition of Mellow Hope, China
Date:2/20/2009

BEIJING, Feb. 20 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com is pleased to announce that it has closed the merger agreement with Shenzhen Mellow Hope Pharm Industrial Co., Ltd. (Mellow Hope). The acquisition has been structured through a Belize based corporation; HTDS Enterprises, Inc., which is the parent company of Mellow Hope. The acquisition is valued at $8.75 million USD on an all-stock basis. The company will issue 3.5 billion restricted shares valued at 0.0025 to Mellow Hope. This will bring the outstanding share structure to 4.75 billion shares.

The merger was announced in a formal televised ceremony on Monday, February 16th. A sampling of television and press coverage can be viewed at the following websites;

    -   Television: www.sztv.com.cn
    -   Shanghai Security Daily and China Security Daily Report:
       http://www.cnstock.com/paper_new/html/2009-02/17/content_66969010.htm
    -   Hong Kong and China Phoenix TV report:
       http://finance.ifeng.com/zq/qqgs/zbsc/20090218/383646.shtml
    -   China investment Daily report:http://www.chnvc.com/news/a11447.html
    -   China's largest internet portal: 'Sohu report':
       http://stock.sohu.com/20090217/n262295189.shtml
    -   China largest finance portal 'JRJ.com':
       http://finance.jrj.com.cn/2009/02/1806113600127.shtml

The agreement will see Mellow Hope join Slavica Bio Chem as an active operating division of HTDS. Located in Serbia, Slavica's primary focus involves the enhancement and modification of existing approved drugs to achieve chemical repair of damage to the CNS (central nervous system) by diseases like MS (Multiple Sclerosis), SARS, Hepatitis C and HIV.

Mellow Hope is the biggest exporter of Biological Vaccines in China, and has a product line that encompasses vaccines for hepatitis A Vaccine, Group A,C,Y,W135 meningococcal polysaccharide vaccine, influenza, tetanus, diphtheria and other diseases; cerebroprotein hydrolysate for injection and active pharmaceutical ingredient (or APIs).

Mellow Hope's Hepatitis A Vaccine (sold under the brand name MEVAC-A) will enter the Thailand market for the first time this March. Additionally, the vaccine was recently certified in Russia, and will be marketed there beginning this May. In total, the Company is in the process of registration and clinical trials in more than 20 countries in Southeast Asia, Latin America and East Europe.

Plans for growth also include building of a larger cold warehouse, developing new vaccines, such as HPV and the establishment of new offices in Yunnan, Wuhan, Kunming as well as India, and the Philippines.

Mellow Hope revenues are currently in excess of $15 million USD.

HTDS CEO, Shimin (Terry) Yuan, commented; "With the full resources of a publicly traded company, and medical experts and management in place on two continents, there will be many opportunities to create synergies between the companies. Despite issues related to the global economic slowdown, there are very many Companies in China such as Mellow Hope that will continue to expand and grow at a rapid pace."

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

Get the Facts Right. The issuer works hard to continue to keep our shareholders informed, and news is updated frequently via Press Releases, Pink Sheet http://www.pinksheets.com/ filings, and updates to our websites. Other websites not sponsored, or recognized by the Company may provide misleading or disinformation to investors in order to manipulate trading patterns for a given stock. Always look for original content from trusted sources, rather than relying on 'excerpts' or discussion boards that may not give you the whole story. The Securities and Exchange Commission requires financial institutions or brokerage firms to provide their clients with documentation, describing the risks of investing in penny stocks.

CONTACT: For scientific dialogue and inquiry only, contact Andrea Zecevic via e-mail at azconsulting2001@gmail.com; For any corporate matters, readers should contact the company directly at corporate@htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Advances May Treat Stroke Faster, Better
2. CONBRIZA Receives Positive CHMP Opinion for the Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
3. High Achieving Los Angeles Charter School to Hold Health Fair Offering Free Medical Screening, Treatment and Information to Students and Their Families
4. SOLX Announces 1000th Gold Shunt Implantation Milestone for Glaucoma Treatment
5. New therapy with stem cells to treat Crohns disease
6. Landmark Trial Provides Vital Information for Cardiac Disease Treatment
7. Research increases possibilities of personalizing treatment of infant osteosarcoma
8. Renaissance Laser & Vein Institute (LaserandVeinclinic.com) Provides Top Notch Varicose Vein Treatment
9. Public Cancer Center Becomes First in South-East Asia to Introduce RapidArc Radiotherapy Treatments From Varian Medical Systems
10. Newly Published Menopause Study: Bioidentical and FDA-Approved Divigel(R) (estradiol gel) 0.1 Percent Safe and Effective Treatment for Moderate to Severe Hot Flashes Associated With Menopause
11. Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 22, 2017 , ... The Rett Syndrome ... devastating neurological disorder that afflicts 350,000 individuals worldwide. Rett Syndrome is caused ... almost exclusively strikes females. Following a normal infancy, Rett Syndrome takes effect ...
(Date:3/22/2017)... , ... March 22, 2017 , ... Last year, 43 ... a US Department of Agriculture report. While excess dairy can be caused by ... role. Lactose sensitivity is the inability to properly digest lactose, a sugar found in ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Tyler Hitchcock Agency, a ... across eastern Texas, is announcing a charity drive in conjunction with the North ... adults. , Consistently a top-rated nonprofit organization for hunger relief, the North ...
(Date:3/22/2017)... ... 2017 , ... Martin J. Mitchell Insurance, a Columbus area ... central Ohio, is initiating a charity drive to raise support for nearby veterans ... the Veteran's Brain Injury Center conclude that more than one in five of ...
(Date:3/22/2017)... ... March 22, 2017 , ... NYC Chiropractor Dr. Steven Shoshany recently helped host ... its kind in the U.S. and focused on a new protocol for treating pain. ... to New York, and furthermore the first seminar in the country was hosted ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... March 22, 2017 A new independent ... is the proven ultraviolet-C (UV-C) disinfection solution of ... (HAIs). Published in the March ... Control , the peer-reviewed study of UV-C disinfection ... Vancouver General Hospital and Rochester General Hospital. According ...
(Date:3/22/2017)... -- FinancialBuzz.com News Commentary  ... According to a report by the New Frontier ... in 2016, and is projected to grow at a compound annual ... by 2025. The medical cannabis market is projected to grow at ... to an estimated $13.3 billion in 2025. These projections do not ...
(Date:3/22/2017)... , March 22, 2017 TFS is ... and Mr. Ed Tumaian , two global executive positions in ... be joining the Operational Leadership Team and will report to Dr. ... ... comes to TFS with 10 years of medical and scientific expertise ...
Breaking Medicine Technology: